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ABSTRACT 
Objectives Despite avoiding HIV infection, HIV-exposed uninfected (HEU) infants have 
poorer clinical outcomes than HIV-unexposed infants, including impaired growth. The 
growth hormone (GH) axis is an important regulator of infant growth through hepatic 
synthesis of insulin-like growth-factor-1 (IGF-1), and may be disrupted by chronic 
inflammation and acute infections, including cytomegalovirus (CMV). We tested the 
hypothesis that these factors lead to disruption of the GH axis in HEU infants, which might 
contribute to their impaired growth. 
Design: Sub-study of 343 infants from the ZVITAMBO trial in Harare, Zimbabwe. 
Methods: IGF-1, growth parameters, C-reactive protein (CRP) and CMV viremia were 
evaluated in 243 HEU infants and 100 HIV-unexposed infants. Univariable linear and logistic 
regression models were used to determine associations between IGF-1 and growth 
parameters, CRP and CMV. 
Results: Mean 6-week IGF-1 was significantly lower in HEU compared to HIV-unexposed 
infants (29.6 vs. 32.6ng/mL; P=0.01), and associated with subsequent linear and ponderal 
growth through 6 months of age. CRP was inversely correlated with IGF-1 in all infants 
regardless of HIV exposure status (β=-0.84; P=0.03). CMV viral loads were inversely 
correlated with IGF-1 in HEU (β=-1.16; P=0.008) but not HIV-unexposed (β=0.21; P=0.83) 
infants. 
Conclusions: Overall, we found evidence for greater disruption of the GH axis in HEU 
compared to HIV-unexposed infants as early as 6 weeks of age, suggesting a role for reduced 
IGF-1 in mediating growth impairment in HEU infants. Inflammation and co-infections may 
be drivers of growth impairment in HEU infants by disrupting the growth hormone axis. 
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INTRODUCTION 
HIV-exposed uninfected (HEU) infants have poorer growth than HIV-unexposed infants
1-3
. 
Impaired linear growth is associated with increased mortality, reduced neurodevelopment and 
lower human capital. Although the pathogenesis of growth failure remains unclear, systemic 
inflammation and co-infections such as cytomegalovirus (CMV) may contribute.
4,5
 The 
growth hormone (GH) axis regulates infant growth through hepatic synthesis of insulin-like 
growth-factor-1 (IGF-1),
6
 which is disrupted by chronic inflammation
7





 We recently showed that Zimbabwean HEU infants have elevated 
inflammatory markers, a high prevalence of CMV infection in early life, and higher CMV 
viral loads compared to HIV-unexposed infants.
10
 Here, we tested the hypothesis that these 
factors suppress the GH axis and contribute to impaired growth in HEU infants. 
METHODS 
The ZVITAMBO trial was undertaken prior to maternal or infant ART availability (1997-
2001).
11
 Briefly, 14110 mother-infant pairs were recruited at birth and followed for 1-2 years. 
Exclusion criteria included birthweight <1500g, plans to leave Harare, multiple pregnancy, 
and life-threatening medical conditions. Mothers underwent longitudinal HIV testing.
11
 
Longitudinal blood samples from children were cryopreserved; the last available sample was 
HIV-tested by DNA PCR (Roche Amplicor,v1.5) or ELISA (GeneScreen;Sanofi Diagnostics 
Pasteur) depending on age. HEU infants in this study were defined as infants born to HIV-
positive mothers who remained HIV-negative through 6-months of age. 
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Infant selection 
We selected all HEU infants in whom mother and infant survived through 6-months, with 
available infant anthropometry and IGF-1 measurement from 6-weeks of age. A random 
selection of 100 HIV-unexposed infants meeting these criteria provided comparative data. 
Anthropometry 
Weight, length and head circumference were measured at birth, 6wks, 3mo and 6mo using 
previously described methods,
12




Plasma IGF-1 and C-reactive protein (CRP) were measured by ELISA (R&D Systems, MN). 
Viral nucleic acid was extracted from plasma using the QIAamp DSP Virus Spin Kit 
(Qiagen, Hilden), and CMV was detected by quantitative PCR using the Abbott RealTime 





We used unpaired t-tests and Mann-Whitney tests to compare continuous variables, and 
Fisher’s exact tests for categorical variables. Univariable linear and logistic regression was 
used to determine associations between IGF-1 and growth. Where there was a possible 
interaction with HIV exposure (P <0.2), results were stratified by maternal HIV status. We 
used univariable linear and logistic regression to determine associations between IGF-1 and 
CRP and CMV, and to determine the modifying effect of HIV exposure. Where there was a 
possible interaction with HIV exposure (P <0.2), analyses were stratified, and multivariable 
linear regression was used to adjust for maternal HIV disease severity. Analyses were 
undertaken using Prism v6.0 (Graphpad, CA) and STATA v15.1 (StataCorp, TX). 
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Ethical approvals 
Mothers provided written informed consent. The trial and this sub-study were approved by 
the Medical Research Council of Zimbabwe, Johns Hopkins Bloomberg School of Public 
Health Committee on Human Research, and Montreal General Hospital Ethics Committee. 
RESULTS 
243 HEU and 100 HIV-unexposed infants were included. Baseline characteristics are shown 
in Supplementary Table 1, http://links.lww.com/QAD/B799. HEU and HIV-unexposed 
infants were similar at baseline, but HEU infants were born to mothers with lower mid-upper 
arm circumference (25.6 vs. 26.2cm;P=0.04) and haemoglobin (113 vs. 121g/L;P=0.005), 
and there were differences in breastfeeding.
10
 Although there were no statistically significant 
differences in growth between HEU and HIV-unexposed infants in this sub-study 
(Supplementary Table 1, http://links.lww.com/QAD/B799), analysis of the whole 
ZVITAMBO cohort (N=14,110) demonstrated significantly poorer growth amongst HEU 
compared to HIV-unexposed infants.
2
 
IGF-1 and growth 
Mean IGF-1 at 6-weeks was lower in HEU infants (29.5ng/mL (SD 10.2) than HIV-
unexposed infants (32.6ng/mL (10.4);P=0.014;Figure 1A). Table 1 shows associations 
between IGF-1 and growth from univariable linear regression analyses. Six-week IGF-1 was 
associated with length-for-age Z-score (LAZ) between 6wks-6mo (Figure 1B). The effect of 
IGF-1 on LAZ was not modified by infant HIV exposure status (all time-points P>0.2). IGF-
1 was positively associated with weight-for-age Z-score (WAZ) at all time-points, and not 
modified by HIV exposure (P >0.2). IGF-1 was positively associated with weight-for-length 
Z-score (WLZ) at 6wks; there was some evidence that this association was modified by HIV 
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exposure at 3 months and 6 months of age. We therefore stratified results by HIV exposure 
status, and found associations between IGF-1 and WLZ in HIV-unexposed but not HEU 
infants at 3 and 6mo. IGF-1 was not significantly associated with head circumference-for-age 
Z-scores (HCZ) between birth and 3mo. However, there was some evidence that the 
association between IGF-1 and HCZ was modified by HIV exposure at 6mo; when results 
were stratified, there was an association in HIV-unexposed infants (β=2.39x10
-2
;P=0.04) but 
not HEU infants (β=0.28x10
-2
;P=0.72). 
Taken together, IGF-1 at 6wks was lower in HEU compared to HIV-unexposed infants. IGF-
1 was associated with future linear growth in HEU infants and with both linear and ponderal 
growth in HIV-unexposed infants. 
Inflammation and IGF-1 
We hypothesised that a pro-inflammatory state is associated with lower circulating IGF-1. 
CRP was measured in 324/343 (94%) infants. On univariable linear regression, there was an 
inverse relationship between log CRP and IGF-1 at 6 weeks of age (β=-0.84;P=0.03; Figure 
1C), which was not modified by HIV exposure status (P=0.97). CRP was not directly 
associated with anthropometric measures (data not shown). 
CMV DNAemia and IGF-1 
We hypothesised that CMV affects growth by disrupting the GH axis. Plasma CMV was 
measured in 331/343 (97%) infants at 6 weeks of age. 81.4% and 74.0% of HEU and HIV-
unexposed infants had CMV DNAemia. We found no difference in mean (SD) IGF-1 
between infants with (30.1 (10.1) ng/mL) or without (31.5 (11.4) ng/mL) CMV DNAemia 
(P=0.30), regardless of HIV exposure (interaction P=0.25). However, among infants with 
CMV DNAemia, there was an inverse relationship between log CMV viral load and IGF-1 
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(β=-1.04;P=0.01), which was modified by HIV exposure (P=0.16): when disaggregated by 
HIV status, the relationship between log CMV viral load and IGF-1 was significant in HEU 
(β=-1.16;P=0.008;Figure 1D) but not HIV-unexposed (β=0.21;P=0.83) infants. The 
relationship in HEU infants was not confounded by maternal HIV disease severity: the 
association between log CMV viral load and IGF-1 in HEU infants persisted after adjusting 
for maternal CD4 count and HIV viral load (β=-1.25;P=0.02). The relationship was also not 
mediated through CRP (after adjusting for CRP, β=-1.00;P=0.016). 
Taken together, detection of CMV was not associated with IGF-1 levels, but among those 
with CMV DNAemia, CMV viral load was inversely associated with IGF-1 in HEU, but not 
HIV-unexposed infants; this finding was not explained by maternal HIV disease severity or 
the inflammatory milieu in HEU infants. 
Effect of trial arm 
Because this sub-study was nested in a placebo-controlled trial of maternal and/or infant 
vitamin A, data were also analysed with adjustment for trial arm, with no meaningful effects 
on findings (Supplementary Table 2, http://links.lww.com/QAD/B800). 
DISCUSSION 
Delineating the mechanisms underlying growth failure in HEU infants is necessary to design 
interventions to promote healthy growth and development in this expanding population.
3
 We 
have previously hypothesised that drivers of growth impairment include inflammation, viral 
co-infections, and maternal HIV disease.
4
 The current study has four key findings. First, HEU 
infants had modest reductions in IGF-1 compared to HIV-unexposed infants at 6wks of age; 
second, IGF-1 concentrations at 6wks were associated with subsequent linear growth through 
6 months amongst HEU children; third, IGF-1 was inversely related to CRP, suggesting that 
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systemic inflammation may reduce IGF-1 levels;
6
 and, fourth, CMV viral load was inversely 
related to IGF-1 in HEU infants but not in HIV-unexposed infants. Collectively, these 
findings suggest independent effects of early-life CMV acquisition and systemic 
inflammation in disruption of the GH axis in HEU infants. 
GH is an important regulator of infant growth through hepatic synthesis of IGF-1.
6
 Here we 
show that IGF-1 is approximately 10% lower in HEU compared to HIV-unexposed infants as 
early as 6-weeks. Six-week IGF-1 was associated with length and weight at most subsequent 
time points, suggesting that lower concentrations of IGF-1 could plausibly contribute to 
growth impairment in HEU infants. There was evidence that HIV exposure modified the 
association between IGF-1 and WLZ and HCZ, such that the effect was more pronounced in 
HIV-unexposed infants. This may indicate a greater, or different, range of drivers of growth 
failure in HEU compared to HIV-unexposed infants,
4
 and should be investigated further. 
In a previous study among HIV-unexposed infants from this cohort, we reported that stunting 
is characterized by chronic inflammation, which appears to disrupt the GH axis,
7
 as in other 
inflammatory diseases.
6
 We also reported raised inflammatory markers among HEU infants 
from as early as 6-weeks of age.
10
 Here we extend these findings by showing that the inverse 
relationship between IGF-1 and CRP is not modified by HIV-exposure status, meaning 
inflammation in HEU infants likely contributes to growth impairment through reduced IGF-1 
as in HIV-unexposed infants. Whether raised inflammatory markers persist in the PMTCT 
era remains unknown and warrants investigation. 
The ZVITAMBO trial reported increased frequency and severity of common childhood 
infections in HEU infants
4
 and a failure to effectively control CMV infection.
10
 We have also 
shown in the same cohort that acute clinical infections disrupt the GH axis.
8
 CMV has 
previously been associated with impaired growth among HIV-exposed and HIV-unexposed 
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children in Zambia.
14
 Here we hypothesised that CMV viraemia contributes to disruption of 
the GH axis. The presence of CMV DNAemia at 6 weeks had no association with IGF-1; 
however, among HEU (but not HIV-unexposed) infants with CMV viraemia, there was an 
inverse relationship between CMV viral load and IGF-1 concentrations. This is consistent 
with our previous finding that HEU infants have impaired handling of infections,
10,15
 and 
suggests this may have consequences for growth. Importantly, the relationship between CMV 
viral load and IGF-1 was not explained by severity of maternal HIV, or by elevated 
inflammatory markers in those infants with higher CMV viral loads. Collectively, these 
findings indicate two distinct potential mechanisms underlying growth failure in HEU 
infants: chronic inflammation and impaired control of viral infections.  
This study has strengths and limitations. HIV-exposed infants were known to be HIV-
uninfected to at least 6 months of age, meaning the group was not contaminated by infants 
becoming postnatally HIV-infected through breastfeeding. The trial took place before ART 
availability, meaning positive or negative effects of ART on growth were eliminated. We 
included all available HEU infants in this analysis; however, it is possible that the study was 
underpowered to identify true modifying effects of HIV exposure. Measuring CRP only may 
not have fully captured the inflammatory milieu, including CMV-related inflammation. We 
were unable to delineate causal relationships, but our findings warrant further mechanistic 
exploration. 
In summary, we find evidence for greater disruption of the GH axis in HEU compared to 
HIV-unexposed infants by 6 weeks of age, which suggests a potential role for reduced IGF-1 
in mediating growth impairment in HEU infants. The previously reported pro-inflammatory 
state of HEU infants likely represents one pathway underlying growth impairment, but we 
also found an independent association between greater CMV viraemia and reduced IGF-1, 
suggesting that both chronic inflammation and poor handling of infections might contribute 
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to stunting in HEU infants. These pathways provide an opportunity to evaluate targeted 
interventions for HEU infants, to promote healthy growth and development. 
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 Figure 1. IGF-1, growth, inflammation and cytomegalovirus. (A) IGF-1 concentration at 
6 weeks of age in HIV-exposed uninfected versus HIV-unexposed children. Horizontal lines 
at mean. (B) Association between IGF-1 concentration and length-for-age Z-score at 6 
months of age amongst HIV-exposed uninfected (black circles) and HIV-unexposed (white 
circles) children. Line shows regression with 95% confidence intervals amongst all children. 
(C) Association between C-reactive protein and IGF-1 concentrations at 6 weeks of age 
amongst HIV-exposed uninfected (black circles) and HIV-unexposed (white circles) children. 
Line shows regression with 95% confidence intervals amongst all children. (D) Association 
between CMV viral load and IGF-1 concentration in CMV-viremic HIV-exposed uninfected 
(black circles) and HIV-unexposed (white circles) children. HIV exposure status modified the 
effect of CMV viral load on IGF-1, so two regression lines are shown. The black line shows 
regression with 95% confidence intervals for HIV-exposed uninfected children. The white 
line shows regression with 95% confidence intervals for HIV-unexposed children. IGF-1: 
insulin-like growth factor-1; CMV cytomegalovirus. 
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Table 1. Associations between insulin-like growth factor-1 at 6 weeks of age and infant 
growth 
 
 Age at anthropometry measurement 
 Birth  6 wk  3 mo  6 mo  
Length-for-age Z score 
6wk IGF-1 (ng/mL) x 
HIV exposure 
(interaction) 















, P = 
0.007 
Weight-for-age Z score 
6wk IGF-1 (ng/mL) x 
HIV exposure 
(interaction) 
P = 0.82 P = 0.72 P = 0.21 P = 0.49 
Regression βIGF-1 1.22x10
-2












, P = 
0.001 
Weight-for-length Z score 
6wk IGF-1 (ng/mL) x 
HIV exposure 
(interaction) 
P = 0.51 P = 0.79 P = 0.14# P = 0.16# 








, P = 
0.02 
- - 
HEU regression βIGF-1 - - 0.49x10
-2














, P = 
0.03 
Head circumference-for-age Z score 
6wk IGF-1 (ng/mL) x 
HIV exposure 
(interaction) 
P = 0.57 P = 0.25 P = 0.38 P = 0.13# 












, P = 
0.08 
- 
HEU regression βIGF-1 - - - 0.28x10
-2




- - - 2.39x10
-2
, P = 
0.04 
All associations estimated by univariable linear regression. 
HEU: HIV-exposed uninfected; IGF-1: insulin-like growth factor-1; #P <0.2 (significance 
level for interaction). 
*The β co-efficient shows the change in Z-score for each anthropometry variable per unit rise 
in IGF-1 (measured in ng/mL). 
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